Discovery of Triazolyl Derivatives of Cucurbitacin B Targeting IGF2BP1 against Non-Small Cell Lung Cancer
Journal of Medicinal Chemistry · 2023
DOI: 10.1021/acs.jmedchem.3c00872 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2023. Verfasst von Fan-Fan Shang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Natural Medicines of the Changbai Mountain, Ministry of Education, College of Pharmacy, Yanbian University, Yanji 133002, China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Triterpenes, Antineoplastic Agents. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 40 Literaturangaben. Gefördert von: Shanghai Jiao Tong University, Yanbian University, Science and Technology Commission of Shanghai Municipality.
Abstract (Originalsprache)
Cucurbitacin B (CuB) is a potent but toxic anticancer natural product. Herein, we designed and synthesized 2-OH- and 16-OH-modified CuB derivatives to improve their antitumor efficacy and reduce toxicity. Among them, derivative A11 had the most potent antiproliferative activity against A549 lung cancer cells (IC50 = 0.009 μM) and was approximately 10-fold more potent than CuB, while the cytotoxicity of A11 toward normal L02 cells was about 10-fold less potent, indicating a much wider therapeutic window than CuB. Derivative A11 directly binds to the insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) protein with a KD value of 2.88 nM, which is about 23-fold more potent than CuB, leading to the decreased expression of downstream apoptosis- and cell cycle-related proteins. More importantly, A11 exhibited much more potent anticancer efficacy in an A549 xenograft mouse model with a TGI rate of 80% and a superior in vivo safety profile than that of CuB.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Key Laboratory of Natural Medicines of the Changbai Mountain, Ministry of Education, College of Pharmacy, Yanbian University, Yanji 133002, China.
- Shanghai Frontiers Science Center of Drug Target Identification and Delivery, National Key Laboratory of Innovative Immunotherapy, School of Pharmaceutical Sciences, Shanghai Jiao Tong University, Shanghai 200240, China.
- Key Laboratory of Natural Medicines of the Changbai Mountain, Ministry of Education, College of Integration Science, Yanbian University, Yanji 133002, China.
ORCID-Profile: Zhe-Shan Quan, Chunyong Ding
Förderung
- Shanghai Jiao Tong University
- Yanbian University
- Science and Technology Commission of Shanghai Municipality
- National Natural Science Foundation of China
Zitieren
APA
Shang, F. F., Lu, Q., Lin, T., Pu, M., Xiao, R., Liu, W., Deng, H., Guo, H., Quan, Z. S., Ding, C., & Shen, Q. K. (2023). Discovery of Triazolyl Derivatives of Cucurbitacin B Targeting IGF2BP1 against Non-Small Cell Lung Cancer. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.3c00872
Vancouver
Shang FF, Lu Q, Lin T, Pu M, Xiao R, Liu W, et al. Discovery of Triazolyl Derivatives of Cucurbitacin B Targeting IGF2BP1 against Non-Small Cell Lung Cancer. Journal of Medicinal Chemistry. 2023. doi:10.1021/acs.jmedchem.3c00872
BibTeX
@article{Shang2023,
author = {Shang, Fan-Fan and Lu, Qing and Lin, Tailiang and Pu, Miaoxia and Xiao, Ruoxuan and Liu, Wanmei and Deng, Hao and Guo, Hongyan and Quan, Zhe-Shan and Ding, Chunyong and Shen, Qing-Kun},
title = {Discovery of Triazolyl Derivatives of Cucurbitacin B Targeting IGF2BP1 against Non-Small Cell Lung Cancer},
journal = {Journal of Medicinal Chemistry},
year = {2023},
doi = {10.1021/acs.jmedchem.3c00872}
}
EUVIMED